Menu
Recruiting NCT07462013

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice

No phase Interventional Major Depressive Disorder (MDD)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Soybean oil (Standard treatment), Eicosapentaenoic acid (omega-3 fatty acid).
Who it may be relevant to
Registry conditions: Major Depressive Disorder (MDD). Basic parameters: 50 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER)

Overview

POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).

Interventions

  • Dietary supplement Soybean oil (Standard treatment)
    3g/day of Soybean Oil
  • Dietary supplement Eicosapentaenoic acid (omega-3 fatty acid)
    3 grams/day

Primary outcome measures

  • Depressive Symptoms [Time frame: Weeks 0, 4, 8, 12, 16, 24]
  • Depressive Symptoms [Time frame: Weeks 0, 4, 8, 12, 16, 24]
  • Depressive Symptoms [Time frame: Weeks 0, 4, 8, 12, 16, 24]
  • Depressive Symptoms [Time frame: Weeks 0, 4, 8, 12, 16, 24]
  • Executive Functioning [Time frame: Weeks 0, 4, 12, 24]
  • Executive Functioning [Time frame: Weeks 0, 4, 12, 24]
  • Executive Functioning [Time frame: Weeks 0, 4, 12, 24]
  • General Cognitive Ability and Memory & Attention [Time frame: Weeks 0, 4, 12, 24]
  • Processing Speed [Time frame: Weeks 0, 4, 12, 24]
Secondary outcome measures (2)
  • Gut microbiome composition [Time frame: Weeks 0 and 24]
  • Fatty Acids Profiles in Blood [Time frame: Weeks 0 and 24]

Eligibility criteria

Inclusion criteria

  • Aged 50-80 years old
  • Major Depressive Disorder
  • Absence or mild cognitive impairment

Exclusion criteria

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Taiwan · 1 center
  • Mind Body Interface Research Center (MBI Lab & Care) — Taichung

Identifiers

NCT: NCT07462013 · CMUH114-REC3-136

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗